Immutep Ltd (YP1B) Price & Analysis

0 Followers

YP1B Stock Chart & Stats

€0.02

€0.00(0.00%)

At close: Jul 30 4:00 PM EDT

€0.02

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.01 - €0.25

Previous CloseN/A

Volume0.00

Average Volume (3M)869.00

Market Cap

€41.17M

Enterprise Value€10.28

Total Cash (Recent Filing)€68.87M

Total Debt (Recent Filing)€1.05M

Price to Earnings (P/E)―

Beta2.58

Next Earnings

Feb 25, 2027

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding1,473,721,300

10 Day Avg. Volume2,607

30 Day Avg. Volume869

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)1.27

Price to Sales (P/S)5.36

P/FCF Ratio-1.40

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€0.04

Price Target Upside117.29% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)>-0.01

Revenue Forecast (FY)€2.38M

Bulls Say, Bears Say

Bulls Say

Revenue AccelerationSharp revenue acceleration indicates improving commercial traction and greater monetization of the company’s biotechnology programs. If sustained, stronger top-line growth can spread fixed operating costs, support investment in clinical development, and improve the path toward future operating leverage.

Gross Margin ImprovementThe substantial gross-margin rebound suggests that the revenue mix or economics of current activities have improved meaningfully. Maintaining this level would provide more gross profit to fund research and development, absorb corporate costs, and support a more durable route toward profitability.

Low Financial LeverageVery low debt reduces interest burden and limits balance-sheet pressure while the company funds clinical and commercial activities. Positive equity also provides a capital buffer, giving management more flexibility than a highly leveraged biotechnology business if operating performance improves.

Bears Say

Persistent UnprofitabilityThe large net loss shows that improved revenue and gross margin have not yet translated into financial sustainability. Continued operating expense intensity can consume capital for an extended period, leaving future earnings dependent on substantial growth, cost control, or successful development outcomes.

Heavy Cash BurnMaterially negative operating and free cash flow means the business remains cash consumptive despite its revenue growth. Ongoing burn can require external funding until operating scale improves, potentially limiting strategic flexibility and increasing the importance of disciplined capital allocation.

Equity ErosionThe sharp reduction in equity weakens the company’s capital cushion and is consistent with the impact of ongoing losses and possible capital-structure changes. If losses persist, further funding needs could increase dilution risk and reduce the resources available for long-term development.

Immutep Ltd News

Immutep provides update on development strategy for eftilagimod alfa

Immutep (IMMP) provided an update on its development strategy for eftilagimod alfa. Following the early discontinuation of the...

8d ago

RDY

IMMP

Immutep Refocuses Efti Development After Manufacturing Probe

An announcement from Immutep Ltd ( ($AU:IMM) ) is now available. Immutep has outlined a focused development strategy...

9d ago

S&P Dow Jones Indices Unveils September Rebalance of Key S&P/ASX Benchmarks

An update from Immutep Ltd ( ($AU:IMM) ) is now available. S&P Dow Jones Indices has announced the...

16d ago

Immutep Revenue Jumps on Dr Reddy’s Deal but Loss Widens on R&D Spend

Immutep Ltd ( ($AU:IMM) ) has shared an announcement. Immutep reported a sharp increase in total revenue for...

20d ago

Immutep balances TACTI-004 setback with upbeat efti and IMP761 data

Immutep Ltd ( ($AU:IMM) ) has issued an announcement. Immutep’s latest quarterly update underscores its role in cancer...

2M ago

Immutep’s Sarcoma Quality-of-Life Data Accepted for ESMO 2026

Immutep Ltd ( ($AU:IMM) ) has shared an update. Immutep has had an abstract accepted for presentation at...

2M ago

Immutep granted new patent for eftilagimod alfa combination

Immutep (IMMP) announced the grant of a new patent entitled “Combined Preparations for the Treatment of Cancer or...

2M ago

IMMP

Immutep Wins Fourth U.S. Patent for Key Cancer Immunotherapy Combination

An update from Immutep Ltd ( ($AU:IMM) ) is now available. Immutep Limited has secured its fourth U.S....

2M ago

Immutep Posts Strong NSCLC Survival Data as It Probes Phase III Setback

The latest update is out from Immutep Ltd ( ($AU:IMM) ). Immutep reported mature overall survival data from...

2M ago

JPMorgan Group Ceases to Be Substantial Holder in Immutep

An announcement from Immutep Ltd ( ($AU:IMM) ) is now available. JPMorgan Chase & Co and its affiliates...

3M ago

Immutep upgraded to Buy from Hold at Maxim

Maxim analyst Jason McCarthy upgraded Immutep (IMMP) to Buy from Hold with a $1.50 price target Published first...

3M ago

IMMP

JPMorgan Chase Ceases to Be Substantial Holder in Immutep

Immutep Ltd ( ($AU:IMM) ) has provided an update. JPMorgan Chase & Co. and its affiliates have notified...

3M ago

JPMorgan Ceases to Be Substantial Holder in Immutep Ltd

Immutep Ltd ( ($AU:IMM) ) has shared an announcement. JPMorgan Chase & Co. and its affiliates have notified...

3M ago

Immutep to present positive interim Phase I data for IMP761

Immutep (IMMP) announced it will present first-in-human clinical data for its lead autoimmune candidate, IMP761, at the European...

4M ago

IMMP

YP1B FAQ

What was Immutep Ltd’s price range in the past 12 months?

Immutep Ltd lowest stock price was €0.01 and its highest was €0.25 in the past 12 months.

What is Immutep Ltd’s market cap?

Immutep Ltd’s market cap is €41.17M.

When is Immutep Ltd’s upcoming earnings report date?

Immutep Ltd’s upcoming earnings report date is Feb 25, 2027 which is in 159 days.

How were Immutep Ltd’s earnings last quarter?

Immutep Ltd released its earnings results on Sep 02, 2026. The company reported -€0.014 earnings per share for the quarter, missing the consensus estimate of -€0.002 by -€0.012.

Is Immutep Ltd overvalued?

According to Wall Street analysts Immutep Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Immutep Ltd pay dividends?

Immutep Ltd does not currently pay dividends.

What is Immutep Ltd’s EPS estimate?

Immutep Ltd’s EPS estimate is >-0.01.

How many shares outstanding does Immutep Ltd have?

Immutep Ltd has 1,473,721,300 shares outstanding.

What happened to Immutep Ltd’s price movement after its last earnings report?

Immutep Ltd reported an EPS of -€0.014 in its last earnings report, missing expectations of -€0.002. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Immutep Ltd?

Currently, no hedge funds are holding shares in DE:YP1B

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Immutep Ltd Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-43.93%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Immutep Ltd

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

Immutep Ltd (YP1B) Earnings & Revenues

Historic Earnings Reports

YP1B Stock 12 Month Forecast

Average Price Target

€0.04

▲(117.29% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","-1":"-€1","-0.5":"-€0.5","0.5":"€0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.04966704,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€0.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.043458659999999996,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€0.04</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.03725028,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€0.04</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.019,0.021359003076923077,0.023718006153846154,0.02607700923076923,0.028436012307692306,0.030795015384615383,0.03315401846153846,0.03551302153846154,0.037872024615384615,0.04023102769230769,0.04259003076923077,0.04494903384615385,0.04730803692307692,{"y":0.04966704,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.019,0.020881435384615385,0.022762870769230767,0.024644306153846152,0.026525741538461538,0.02840717692307692,0.030288612307692305,0.03217004769230769,0.03405148307692307,0.035932918461538454,0.03781435384615384,0.03969578923076923,0.041577224615384614,{"y":0.043458659999999996,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.019,0.020403867692307693,0.021807735384615383,0.023211603076923076,0.02461547076923077,0.02601933846153846,0.027423206153846153,0.028827073846153843,0.030230941538461537,0.03163480923076923,0.03303867692307692,0.03444254461538461,0.03584641230769231,{"y":0.03725028,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.113,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.138,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.151,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.216,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.22,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.206,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.015,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.023,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.016,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.022,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.016,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.019,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >